Lisa Mariana
A growing number of individuals across the United Kingdom are attributing severe, life-altering addictions, including compulsive gambling, hypersexuality, and excessive spending, to a class of medications prescribed for movement disorders. Over 250 testimonies have been compiled, revealing a deeply troubling pattern where patients, previously free from such destructive behaviours, find their lives irrevocably altered, raising significant questions about pharmaceutical warnings, physician awareness, and regulatory oversight.
The scope of this issue is profound, affecting individuals from all walks of life. Among those who have come forward are highly responsible professionals – including police officers, nurses, medical doctors, and even a director of risk for a major financial institution – whose lives have been destabilized by unexpected compulsions. Their experiences underscore a critical failure in the communication of potential side effects associated with dopamine agonist drugs, nearly a year after initial reports first brought these ruinous consequences to public attention. Despite a recent reclassification downgrading these drugs as a primary treatment for Restless Legs Syndrome (RLS), prescription rates in England have shown no discernible decrease, prompting urgent calls for review from parliamentary figures and expressions of grave concern from government officials.
One poignant illustration of this crisis is the case of Emma, whose journey into compulsive gambling began inexplicably after she was prescribed Ropinirole, a dopamine agonist manufactured by GSK. Emma, who initially developed RLS during pregnancy, a condition often linked to iron levels, found her symptoms worsening over time, leading to the prescription. Unbeknownst to her, the medication was initiating a profound shift in her behaviour. Over the course of a year, she amassed tens of thousands of pounds in gambling losses, alongside impulsive purchases of frivolous items. The overwhelming sensation was one of being controlled by an external force, a feeling that defied her understanding and previous character.
It was only through her husband’s diligent research, uncovering an earlier journalistic investigation into the adverse effects of her medication, that Emma grasped the devastating connection. "I read it and went, ‘Oh my God – that’s me’," she recounted, a stark moment of realization that transformed her perspective on her inexplicable compulsions. Despite Emma’s proactive steps to inform her healthcare providers – including documenting her gambling addiction and her Ropinirole prescription on online forms for GP appointments – she reports that her doctor failed to link her escalating gambling problem to the known side effects of the drug. This significant oversight meant Emma continued on the medication, incurring further financial devastation, ultimately losing at least £30,000. Her personal testimony is chilling: "It’s ruined my life – we’re going to be in debt for God knows how long paying it off."
Dopamine agonists function by enhancing dopamine activity in the brain. Dopamine, a crucial neurotransmitter, is instrumental not only in regulating movement but also in governing motivation, reward, and impulse control. The therapeutic mechanism of these drugs, designed to alleviate symptoms of conditions like RLS and Parkinson’s disease by boosting dopamine, can inadvertently overstimulate the brain’s reward pathways. This overstimulation is believed to trigger the spectrum of impulsive and compulsive behaviours now being reported by hundreds of patients. Beyond gambling, these behaviours encompass hypersexuality, compulsive shopping, binge eating, cross-dressing, and reckless financial investments. Alarmingly, there have been reports of individuals pursuing homosexual relationships for the first time in their lives, and older women describing their long-term partners becoming sexually coercive.
A recurring and deeply concerning theme among these accounts is the complete absence of prior history for such behaviours. Patients and their families alike express shock and bewilderment, having never suspected their medication as the root cause. For Parkinson’s patients, approximately one in six individuals on these drugs experience some form of impulsive behaviour, a prevalence that would classify these side effects as "very common." Yet, this critical information is often omitted from patient information leaflets. Furthermore, the warnings that do exist are frequently criticized for their broad, generic descriptions of "impulsive behaviours" rather than specific, actionable examples such as gambling addiction or hypersexuality, which can include pornography addiction or the pursuit of sex workers.
The tragic consequences of these undisclosed side effects were brought into sharp focus by a recent report detailing a family where both a father and son tragically took their own lives. The father, a solicitor named Andrew, had succumbed to impulsive behaviours induced by his medication, leading him to embezzle £600,000 from his clients to fund sex and antique purchases. Since the publication of this harrowing account, more men have come forward, recognizing Andrew’s reported hypersexuality as a reflection of their own current struggles.
Michael, whose name has been altered to protect his identity, is one such individual. Prescribed dopamine agonists for RLS, he describes a sudden onset of hypersexuality, leading him to engage with approximately 20 sex workers, both male and female, despite being married and having no prior history of infidelity or homosexual encounters. Michael articulates a profound sense of entrapment, initially enjoying the compulsion but now feeling powerless and isolated. He finds himself unable to confide in his doctor, as his wife attends his appointments, and feels he has "nowhere to turn." While charities such as Parkinson’s UK and RLS-UK offer vital support, and the NHS advises patients with concerns to consult their doctor, the internal conflict and societal stigma surrounding these specific addictions create formidable barriers to seeking help.
Further investigations have unearthed deeply disturbing revelations concerning the timeline of pharmaceutical companies’ awareness regarding these extreme side effects. It has been discovered that GSK, the manufacturer of Ropinirole, was aware of a case involving paedophilia linked to its drug as early as 2000. This was seven years before any warnings about sexual urges appeared in patient information. The case involved a 63-year-old man on Ropinirole who sexually assaulted a seven-year-old girl and was subsequently imprisoned. This specific case was then incorporated into a 2003 safety report by GSK, which explicitly described a link between Ropinirole and what the company termed "deviant" sexual behaviour.
GSK asserts that it shared this report with the UK drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), the following year, and had notified them about the paedophilia case within days of its occurrence. However, the precise language of "deviancy" or specific details of such severe behavioural changes have never been explicitly included in patient warnings. Instead, leaflets vaguely mention "increased libido," "harmful behaviour," and "altered sexual interest." Intriguingly, at the same time GSK was compiling these findings, it was also seeking approval to use Ropinirole for RLS and, in 2005, collaborated with a private US hospital to explore the drug’s efficacy as a treatment for sexual dysfunction. GSK has stated that its drug underwent extensive trials, maintains global regulatory approval, and that all known side effects are clearly disclosed. They also clarified that they did not sponsor or design the 2005 trial for sexual dysfunction.
The MHRA has defended the delay in issuing warnings, stating that such decisions require comprehensive consideration of all available evidence and that patient leaflets cannot provide an "exhaustive" list of individualised behaviours. However, this stance offers little solace to the hundreds of patients who feel inadequately warned and without recourse for the devastating impact on their lives.
The lack of apparent avenues for justice within the UK stands in stark contrast to developments internationally. Legal cases abroad are setting precedents, ranging from compensation claims to criminal acquittals. A significant example occurred a year ago in Belgium, where a court acquitted a man accused of sexually assaulting his four-year-old granddaughter. The defence successfully argued that his Ropinirole medication had induced his paedophilic behaviour. Upcoming next month is a pivotal judgment in a French court, where a man in his fifties is suing GSK. He alleges that the medication destroyed his relationship with his partner and led to €90,000 (£78,600) in losses due to compulsive gambling and spending. He is seeking substantial damages and a formal recognition of liability from the pharmaceutical company.
These international legal battles highlight a growing global recognition of the severe, underreported side effects of dopamine agonists and the potential for pharmaceutical companies to be held accountable for inadequate warnings. The UK’s healthcare system and regulatory bodies face increasing pressure to address this systemic issue. This involves not only reviewing and updating patient information leaflets with explicit and detailed warnings about specific addictive behaviours but also ensuring that healthcare professionals are adequately informed and trained to identify and counsel patients about these risks. The ongoing testimonies of hundreds of individuals underscore an urgent need for greater transparency, robust patient education, and a re-evaluation of how adverse drug reactions, particularly those impacting mental and behavioural health, are communicated and managed within the healthcare ecosystem. The profound personal and societal costs of these medication-induced addictions demand a comprehensive and proactive response to prevent further devastation.
Ayu Aulia
Ridwan Kamil
Safa Marwah
Aura Kasih